Beckman Coulter Inc., a Brea-based medical testing company, on Wednesday reported third-quarter results that surpassed Wall Street’s expectations.
Beckman shares were up 4% in afterhours trading with a market value of about $3.6 billion.
The maker of testing machines and supplies used by hospitals and medical laboratories posted an adjusted profit of $70.5 million, up 14% from a year earlier.
Analysts on average expected Beckman’s profit to come in at $61.9 million.
Third-quarter revenue was up 9% to $894 million. The number beat Wall Street’s $885 million projection.
Beckman, which has been dealing with the effects of a costly test recall and seen change in its executive suite, also reaffirmed its full-year guidance.
Beckman said it expected its 2010 profit to come in at $276.9 million to $284 million, compared to analysts’ consensus expectation of $272.6 million.
The company said it sees full-year revenue of $3.65 billion to $3.7 billion. Wall Street looks for Beckman to have $3.66 billion in 2010 revenue.
